Skip to main content
Clinical Trials/NCT04373759
NCT04373759
Completed
N/A

Cardiac Arrest Incidence and Outcome Among Patient With COVID-19 Pneumonia in French ICUs

Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer36 sites in 2 countries186 target enrollmentMay 2, 2020

Overview

Phase
N/A
Intervention
Not specified
Conditions
Sars-CoV2
Sponsor
Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer
Enrollment
186
Locations
36
Primary Endpoint
Incidence of unexpected cardiac arrest
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the novel coronavirus disease 2019 (COVID-19) pandemic. Among COVID-19 complications, in-hospital cardiac arrest (IHCA) was reported with a very poor outcome in a retrospective single-center study (0,7% of 30 days survival with good neurological outcome among IHCA patients with a resuscitation attempt), related to its natural course and management. The incidence of unexpected in-ICU cardiac arrest (ICUCA) due to COVID-19 is still unknown. Additionally, outcome of COVID-19 patients admitted in ICU for an out-of-hospital cardiac arrest (OHCA) is also undescribed.

The objective this study is :

  • to report the incidence of ICUCA among patients hospitalized in French ICU for COVID-19.
  • to report morbidity and mortality among COVID-19 patients admitted alive in ICU for an OHCA or an IHCA.

The secondary objective is to assess outcome and identify risk factors of ICUCA occurrence among patients admitted for COVID-19.

Detailed Description

Retrospective and prospective multicentric observational registry in French intensive care units (ICU) including all consecutive adult patients admitted in ICU with a documented SARS-CoV-2 disease : * For an out-of-hospital or an in-hospital cardiac arrest (OHCA and IHCA respectively) * Or presenting an unexpected in-ICU cardiac arrest (ICUCA) Patients characteristics, cardiac arrest history and patients outcome will be recorded according to Utstein recommendations. Patients presenting an expected cardiac arrest in ICU related to withdrawal of life sustaining therapies (WLST) will be excluded.

Registry
clinicaltrials.gov
Start Date
May 2, 2020
End Date
September 30, 2020
Last Updated
3 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patients admitted in intensive care unit with a documented SARS-CoV-2 disease
  • For an out-of-hospital or an in-hospital cardiac arrest
  • Or an in-hospital cardiac arrest
  • Or presenting an unexpected in-intensive care unit cardiac arrest

Exclusion Criteria

  • Age under 18 y.o
  • Expected in-intensive care unit cardiac arrest related to withdrawal of life sustaining therapies.
  • Withdrawal of patient or next-of-kin informed consent

Outcomes

Primary Outcomes

Incidence of unexpected cardiac arrest

Time Frame: 7 months

Percentage of unexpected in-intensive care unit cardiac arrest among COVID-19 patients admitted to intensive care unit

Secondary Outcomes

  • Charlson score(7 months)
  • Etiology retained to explain cardiac arrest occurrence(7 months)
  • Modified Rankin score (mRS) at ICU discharge, at hospital discharge and at 3 months(3 months)
  • Organ failure score at ICU admission and/or before unexpected in-ICU cardiac arrest(7 months)

Study Sites (36)

Loading locations...

Similar Trials